S&P 500   3,363.00 (+0.83%)
DOW   27,781.70 (+1.20%)
QQQ   277.08 (+0.41%)
AAPL   115.40 (+1.15%)
MSFT   209.36 (+1.01%)
FB   261.33 (-0.18%)
GOOGL   1,464.07 (-0.13%)
AMZN   3,144.98 (+0.00%)
TSLA   428.79 (+2.32%)
NVDA   539.85 (+2.05%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.91 (-7.49%)
GE   6.23 (+1.80%)
AMD   81.35 (-0.51%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   62.90 (+1.29%)
NFLX   500.42 (+1.41%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
S&P 500   3,363.00 (+0.83%)
DOW   27,781.70 (+1.20%)
QQQ   277.08 (+0.41%)
AAPL   115.40 (+1.15%)
MSFT   209.36 (+1.01%)
FB   261.33 (-0.18%)
GOOGL   1,464.07 (-0.13%)
AMZN   3,144.98 (+0.00%)
TSLA   428.79 (+2.32%)
NVDA   539.85 (+2.05%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.91 (-7.49%)
GE   6.23 (+1.80%)
AMD   81.35 (-0.51%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   62.90 (+1.29%)
NFLX   500.42 (+1.41%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
S&P 500   3,363.00 (+0.83%)
DOW   27,781.70 (+1.20%)
QQQ   277.08 (+0.41%)
AAPL   115.40 (+1.15%)
MSFT   209.36 (+1.01%)
FB   261.33 (-0.18%)
GOOGL   1,464.07 (-0.13%)
AMZN   3,144.98 (+0.00%)
TSLA   428.79 (+2.32%)
NVDA   539.85 (+2.05%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.91 (-7.49%)
GE   6.23 (+1.80%)
AMD   81.35 (-0.51%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   62.90 (+1.29%)
NFLX   500.42 (+1.41%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
S&P 500   3,363.00 (+0.83%)
DOW   27,781.70 (+1.20%)
QQQ   277.08 (+0.41%)
AAPL   115.40 (+1.15%)
MSFT   209.36 (+1.01%)
FB   261.33 (-0.18%)
GOOGL   1,464.07 (-0.13%)
AMZN   3,144.98 (+0.00%)
TSLA   428.79 (+2.32%)
NVDA   539.85 (+2.05%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.91 (-7.49%)
GE   6.23 (+1.80%)
AMD   81.35 (-0.51%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   62.90 (+1.29%)
NFLX   500.42 (+1.41%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
Log in
NASDAQ:CHMA

Chiasma Stock Forecast, Price & News

$4.30
-0.05 (-1.15 %)
(As of 09/30/2020 03:59 PM ET)
Add
Compare
Today's Range
$4.24
Now: $4.30
$4.40
50-Day Range
$4.39
MA: $5.00
$5.50
52-Week Range
$2.88
Now: $4.30
$7.75
Volume148,304 shs
Average Volume515,080 shs
Market Capitalization$248.55 million
P/E RatioN/A
Dividend YieldN/A
Beta1.62
Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Needham, Massachusetts.
Read More
Chiasma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.13 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CHMA
CUSIPN/A
Phone617-928-5300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.04 per share

Profitability

Net Income$-36,320,000.00

Miscellaneous

Employees49
Market Cap$248.55 million
Next Earnings Date11/3/2020 (Estimated)
OptionableNot Optionable
$4.30
-0.05 (-1.15 %)
(As of 09/30/2020 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CHMA News and Ratings via Email

Sign-up to receive the latest news and ratings for CHMA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Chiasma (NASDAQ:CHMA) Frequently Asked Questions

How has Chiasma's stock been impacted by Coronavirus?

Chiasma's stock was trading at $3.92 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CHMA shares have increased by 9.7% and is now trading at $4.30.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Chiasma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chiasma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Chiasma
.

When is Chiasma's next earnings date?

Chiasma is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Chiasma
.

How were Chiasma's earnings last quarter?

Chiasma Inc (NASDAQ:CHMA) released its quarterly earnings data on Monday, August, 10th. The biotechnology company reported ($0.50) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.40) by $0.10.
View Chiasma's earnings history
.

What price target have analysts set for CHMA?

4 brokerages have issued 1-year target prices for Chiasma's shares. Their forecasts range from $8.00 to $19.00. On average, they anticipate Chiasma's share price to reach $12.33 in the next twelve months. This suggests a possible upside of 186.8% from the stock's current price.
View analysts' price targets for Chiasma
.

Are investors shorting Chiasma?

Chiasma saw a decline in short interest in the month of August. As of August 14th, there was short interest totaling 1,780,000 shares, a decline of 16.8% from the July 30th total of 2,140,000 shares. Based on an average daily trading volume, of 791,200 shares, the short-interest ratio is currently 2.2 days.
View Chiasma's Short Interest
.

Who are some of Chiasma's key competitors?

What other stocks do shareholders of Chiasma own?

Who are Chiasma's key executives?

Chiasma's management team includes the following people:
  • Mr. Raj Kannan, CEO & Director (Age 56, Pay $475.78k)
  • Mr. Mark J. Fitzpatrick, Pres (Age 57, Pay $788.3k)
  • Mr. Lee Giguere, VP & Gen. Counsel (Age 40, Pay $134.52k)
  • Dr. William H. Ludlam, Sr. VP of Clinical Devel. & Medical Affairs (Age 55, Pay $520.92k)
  • Mr. Drew Enamait, VP of Fin. & Admin. (Age 46)

When did Chiasma IPO?

(CHMA) raised $76 million in an IPO on Thursday, July 16th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. Barclays and Cowen and Company served as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

What is Chiasma's stock symbol?

Chiasma trades on the NASDAQ under the ticker symbol "CHMA."

How do I buy shares of Chiasma?

Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Chiasma's stock price today?

One share of CHMA stock can currently be purchased for approximately $4.30.

How big of a company is Chiasma?

Chiasma has a market capitalization of $248.55 million. The biotechnology company earns $-36,320,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. Chiasma employs 49 workers across the globe.

What is Chiasma's official website?

The official website for Chiasma is www.chiasmapharma.com.

How can I contact Chiasma?

Chiasma's mailing address is 140 Kendrick Street Building C East, Needham MA, 02494. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected]

This page was last updated on 9/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.